Stockscreener 앱 받기
4.40
8.37%
0.34
시간 외 거래:
4.40
Sagimet Biosciences Inc 주식(SGMT)의 최신 뉴스
JPMorgan Chase & Co. Boosts Stake in Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
Brokerages Set Sagimet Biosciences Inc. (NASDAQ:SGMT) Price Target at $23.00 - MarketBeat
Brokerages Set Sagimet Biosciences Inc. (NASDAQ:SGMT) PT at $23.00 - Defense World
Jones Trading Initiates Coverage of Sagimet Biosciences (SGMT) with Buy Recommendation - MSN
Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Sagimet Stock Soars To 10-Month High, Retail’s Fired Up Over Presentation On Lead MASH Drug Candidate - MSN
Barclays PLC Has $159,000 Stock Position in Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
With 43% stake, Sagimet Biosciences Inc. (NASDAQ:SGMT) seems to have captured institutional investors' interest - Simply Wall St
Sagimet Biosciences' SWOT analysis: promising NASH drug faces funding hurdles - Investing.com
Geode Capital Management LLC Acquires 91,246 Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
When (SGMT) Moves Investors should Listen - Stock Traders Daily
Gaining Ground: Sagimet Biosciences Inc (SGMT) Closes Lower at 5.37, Down -3.59 - The Dwinnex
Barclays PLC Boosts Stock Holdings in Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference - The Manila Times
Sagimet to Present Breakthrough MASH Treatment Data at MASH-TAG Conference 2025 - StockTitan
Sagimet Biosciences Updates Investor Presentation in Recent 8-K Filing - Defense World
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives $23.00 Average PT from Analysts - Defense World
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Sagimet Biosciences (NASDAQ:SGMT) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
(SGMT) Trading Advice - Stock Traders Daily
Sagimet Biosciences: A Rising Star in the Fight Against NASH with Promising Clinical Data for Denifanstat - mediahousepress
Sagimet Biosciences up 30% on strong clinical stage data - Mugglehead
Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket - Benzinga
(SGMT) On The My Stocks Page - Stock Traders Daily
Sagimet Biosciences (NASDAQ:SGMT) Research Coverage Started at Oppenheimer - Defense World
Sagimet Biosciences (NASDAQ:SGMT) Now Covered by Analysts at Oppenheimer - MarketBeat
Oppenheimer Initiates Coverage of Sagimet Biosciences (SGMT) with Outperform Recommendation - MSN
Sagimet started at outperform by Oppenheimer, MASH drug cited - MSN
Sagimet started at outperform by Oppenheimer, MASH drug cited (NASDAQ:SGMT) - Seeking Alpha
Oppenheimer sets $30 target on Sagimet Biosciences shares - Investing.com
How To Trade (SGMT) - Stock Traders Daily
Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
Sagimet Biosciences to Present at Piper Sandler Healthcare Conference | SGMT Stock News - StockTitan
Sagimet Biosciences participates ik,on No - TipRanks
Sagimet Biosciences Inc. Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLDthe Liver Meeting 2024 - Marketscreener.com
HC Wainwright Reaffirms “Buy” Rating for Sagimet Biosciences (NASDAQ:SGMT) - Defense World
Sagimet Biosciences keeps stock target with Buy rating on phase 3 program - Investing.com
Sagimet Biosciences presents clinical denifanstat, preclinical FASN inhibitor da - TipRanks
Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLDThe Liver Meeting® 2024 - The Manila Times
3.95%
2.39%
자본화:
|
볼륨(24시간):